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In a single-center study, 66 healthy volunteers aged between 18 and 50 years were randomized to be
immunized against rabies with three different injection routes: intradermal with DebioJectTM (IDJ), stan-
dard intradermal with classical needle (IDS), also called Mantoux method, and intramuscular with clas-
sical needle (IM). ‘‘Vaccin rabique Pasteur” and saline solution (NaCl 0.9%) were administered at D0, D7
and D28. Antigen doses for both intradermal routes were 1/5 of the dose for IM. Tolerability, safety and
induced immunogenicity of IDJ were compared to IDS and IM routes. Pain was evaluated at needle inser-
tion and at product injection for all vaccination visits. Solicited Adverse Event (SolAE) and local reacto-
genicity symptoms including pain, redness and pruritus were recorded daily following each
vaccination visit. Adverse events (AE) were recorded over the whole duration of the study. Humoral
immune response was measured by assessing the rabies virus neutralizing antibody (VNA) titers using
Rapid Fluorescent Focus Inhibition Test (RFFIT). Results demonstrated that the DebioJectTM is a safe, reli-
able and efficient device. Significant decreases of pain at needle insertion and at vaccine injection were
reported with IDJ compared to IDS and IM. All local reactogenicity symptoms (pain, redness and pruritus)
after injection with either vaccine or saline solution, were similar for IDJ and IDS, except that IDJ injection
induced more redness 30 min after saline solution.
No systemic SolAE was deemed related to DebioJectTM and classical needles. No AE was deemed related
to DebioJectTM. No Serious Adverse Event (SAE) was reported during the study.
At the end of the study all participants were considered immunized against rabies and no significant
difference in humoral response was observed between the 3 studied routes.
 2017 The Authors. Published by Elsevier Ltd. This is anopenaccess article under the CCBY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Most vaccinations today consist in administering a high amount
of antigens via the intramuscular (IM) route. Because of the cost of
these antigens and sometimes their shortage in availability, their
use is limited in many developing countries. Intradermal (ID)
administration of several vaccines has been shown to require lower
amounts of antigen than IM vaccination, therefore providing a sig-
nificant economic advantage [1–3]. Four licensed vaccines are cur-
rently delivered ID: smallpox (vaccinia), BCG, influenza
(INTANZA/IDflu, Sanofi Pasteur) and rabies. In particular, in the
case of rabies and influenza, several studies have shown that
reduced doses (typically 10% or 20% of the standard amount ofantigen) delivered ID could induce immune responses similar to
those seen with the standard dose through IM route [1,4–6]. For
these reasons, ID was confirmed to be a promising method for vac-
cination [7].
Skin is considered as a desirable vaccination target since dermis
and epidermis layers are rich sources of antigen-presenting cells
(i.e. Langerhans cells, dermal dendritic cells and dermal macro-
phages) which are known to participate in vaccine induced
immune responses [8,9]. In addition, the dense network of blood
capillaries and lymphatic vessels present within the dermis greatly
facilitates the trafficking of leukocytes and dendritic cells from skin
to the secondary lymphoid organs. However, the Mantoux method
is difficult to execute properly in order to ensure a full delivery into
the dermis. The technique requires specific training and regular
practice of healthcare workers [1,10–12]. Therefore new delivery
devices simplifying intradermal injections and rendering them less
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its specific immune properties more effectively.
DebioJectTM has been designed for this very purpose. The device
is based on a hollow microneedle, whose length is limited to
750 lm to avoid most pain receptors. The microneedle is made
of very strong monocrystalline silicon covered with biocompatible
silicon dioxide. It has an extremely sharp tip and a lateral delivery
aperture located at 500 lm from the base to be minimally invasive
and to ensure drug administration into the dermis without risking
blocking the injection channel (Fig. 1).
DebioJectTM is designed for easy use by medical staff after a very
short training. It is CE marked and can be connected to any stan-
dard syringes. An inserter is used to ensure the full penetration
of the microneedle into the skin in every circumstance.
ID rabies vaccination is promoted by the World Health Organi-
zation (WHO) [13], and has been established for post-exposure
prophylaxis in India, the Philippines, Sri Lanka and Thailand [14–
18]. Rabies is often considered as a good vaccine candidate for
the evaluation of new intradermal device delivery systems [1].
The worldwide burden of human rabies is at an estimated num-
ber of 55,000 deaths per year, occurring predominantly in Asia and
Africa along with canine rabies [13,19–21]. As no effective treat-
ment is available, vaccination is essential to prevent rabies at both
pre- and post-infection stages [16].
Efficient purified rabies vaccines produced in cell-cultures or
embryonated eggs were developed more than four decades ago
[22]. The ‘‘Vaccin rabique Pasteur” manufactured by Sanofi Pas-
teur, a purified rabies vaccine cultured on Vero cells, is WHO-
approved for pre- and post-exposure prophylaxis by ID and IM
routes. WHO recommends a 5-fold antigen dose reduction for the
intradermal route compared to the IM route, which is expected
to induce a rabies virus neutralizing antibody (VNA) respon-
seP 0.5 IU per mL (International Unit/milliliter), considered as
sufficient for protection against rabies [4,22–24].
The objectives of this study were to evaluate DebioJectTM (IDJ)
safety, tolerability and induced immunogenicity compared to stan-
dard intradermal/Mantoux (IDS) and IM route in the frame of
rabies vaccination with ‘‘Vaccin rabique Pasteur”.
2. Materials and methods
2.1. Ethics statement
The study was conducted according to Good Clinical Practice,
the Declaration of Helsinki, Directive 90/385/CEE and 93/42/CEE,
International Standard ISO 14155:2011. The protocol was firstb
750 µm
a
Fig. 1. Schematic cross section (a) and SEM picture (b) of DebioJectTM’s hollow
microneedle with lateral aperture.approved by the local Institutional Review Board (Commission can-
tonale (VD) d’éthique de la recherche sur l’être humain, reference:
178/12) on July 13th, 2012, and then by Swissmedic, the Swiss
Agency for Therapeutic Products (reference: 2012-MD-0030) on
June 3, 2013. EUDAMED Identifier: CIV-12-12-009346. ClinicalTri-
als.gov Identifier: NCT02538185.
2.2. Study design
The study was planned as a single-center, Phase I, first-in-
human pilot study to assess the safety and tolerability of the
DebioJectTM device, and the immunogenicity of the rabies vaccine
‘‘Vaccin rabique Pasteur” delivered with the DebioJectTM device
by intradermal route. In addition to vaccine, saline solution (NaCl
0.9%; B. Braun) was injected in order to complement safety and tol-
erability data. Saline solution was not intended to be used as a pla-
cebo in the immunogenicity evaluation of the ‘‘Vaccin rabique
Pasteur”.
The study was conducted at the Vaccine and Immunotherapy
Center (VIC), which is a specialized unit of the Service of Immunol-
ogy and Allergy of the Centre Hospitalier Universitaire Vaudois
(CHUV) in Lausanne, Switzerland, from August 2013 to September
2014. Both volunteers and investigators were blinded regarding
the injected substance although they both knew the device used
to perform each injection.
2.3. Assessment of IDJ injection completeness
One of the main issues of ID injections based on microneedle is
incomplete injection due to leakage [25]. Injection with IDJ was
considered to be complete if leakage (non-injected fluid residue
present on the skin) represented less than 10% of the volume of
the product to be injected. A procedure was implemented to mea-
sure the amount of non-injected liquid for each IDJ injection. The
procedure consisted of three steps: (1) a blotting paper hermeti-
cally sealed in an Eppendorf tube was weighed. (2) The non-
injected fluid residue present on the skin was immediately
absorbed after the injection with the blotting paper. The blotting
paper was replaced in the Eppendorf tube which was then hermet-
ically sealed. (3) Finally the Eppendorf tube containing the wetted
blotting paper was weighed again with the amount of non-injected
fluid residue corresponding to the weight difference between both
measurements.
2.4. Investigational and comparator devices
The investigational device was DebioJectTM developed by Debio-
tech. The comparator device used for IDS was a 25G needle
mounted on a standard syringe. The comparator device used for
IM injection was a 22G needle mounted on a standard syringe.
The operators involved in the study were selected upon their abil-
ity and experience to perform successful Mantoux injection. They
were also trained to use DebioJectTM.
2.5. Study population
Subjects were recruited in the study only if they were aged
between 18 and 50 years and in good general health, confirmed
by medical history, physical examination and screening laboratory
tests. Female subjects were required to avoid pregnancy through
the duration of the study.
The following criteria caused the exclusion of the study group:
an oral body temperatureP 37.5 C; any history or evidence of
rabies vaccination or rabies contact, autoimmune disease, any pos-
sible immunodeficiency state, including HIV-1 infection, and of
chronic hepatitis; any injection of immunoglobulin or blood
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drug therapy or investigational vaccine within 180 days prior to
study, any licensed vaccine within 45 days prior to study visit 2,
Chloroquin and/or Proguanil treatment within 420 days prior to
study [26]; any use of immunosuppressive drugs or anticoagu-
lants; any Body Mass Index (BMI) 6 18 orP 33; and any immedi-
ate need of rabies immunization.
Ninety-three candidates provided written informed consent at
screening visit. 27 were considered as not eligible, most of which
not meeting the medical inclusion criteria. 66 participants were
enrolled and randomly assigned to one of 3 groups of 22 partici-
pants (group A, B, or C).
The CHUV pharmacist generated a block balanced randomiza-
tion sequence. According to group allocation, participants were
injected with rabies vaccine and saline solution as described in
Table 1. The sequence for each participant consisted of the follow-
ing five visits: one screening visit, three vaccination visits at time
points D0, D7, D28, and one follow-up visit at D56. Study duration
per volunteer was 56 days from the first vaccination to the last
follow-up visit. Table 2 summarizes demographic characteristics
of the subjects enrolled in the study. Due to protocol deviation, 1
subject from group B and 1 from group C were excluded from
analyses.
As age and BMI of the enrolled population were distributed clo-
sely to the corresponding mean values in each study group, these
parameters were not considered as covariates for statistical analy-
ses of safety and immunogenicity results.
2.6. Study product administration
The doses of vaccine injected were 0.1 ml for both ID routes and
0.5 ml for IM route. IDJ injections were performed in the right fore-
arm and IDS in the left one. IDJ and IDS injections were performed
at three different locations corresponding to defined time points:
5 cm (D0), 8 cm (D7) and 11 cm (D28) from the ‘‘fossa cubitalis”.
IM injections were performed in the non-dominant deltoid muscleTable 1
Groups allocation. The 66 subjects were allocated in three groups. Group A: subjects
received vaccine through IDS route; Group B: subjects received vaccine through IDJ
route; Group C: subjects received vaccine through IM route.
Groups Number of
volunteers
Route and volume of administration at three time
points: D0, D7, D28
A 22 Right arm : IDJ with saline solution (0.1 mL)
Left arm : IDS with vaccine (0.1 mL)
Non-dominant deltoid : IM with saline solution
(0.5 mL)
B 22 Right arm : IDJ with vaccine (0.1 mL)
Left arm : IDS with saline solution (0.1 mL)
Non-dominant deltoid : IM with saline solution
(0.5 mL)
C 22 Right arm : IDJ with saline solution (0.1 mL)
Left arm : IDS with saline solution (0.1 mL)
Non-dominant deltoid : IM with vaccine (0.5 mL)
Table 2
Demography. Subjects received vaccine trough standard IDS (Group A), IDJ (Group B), and
Group A
Number of subjects 22
Female number (%) 9 (40.9)
Male number (%) 13 (59.1)
Age [years] Min/Max 18.6/43.3
Mean ± SD 25.4 ± 6.4
BMI [kg m2] Min/Max 18.34/31.64
Mean ± SD 22.8 ± 3.4
The bold values represents the number of subjects per group (e.g. 22 subjects in groupat three different locations corresponding to defined time points:
5 cm (D0), 8 cm (D7) and 11 cm (D28) from the acromion.
2.7. Study vaccine
The vaccine used in this study was the ‘‘Vaccin rabique Pas-
teur” manufactured by Sanofi Pasteur (Lot number J1336, expira-
tion date May 2015), a WISTAR PM/WI 38-1503-3M strain rabies
vaccine, cultured on Vero simian cell cultures, then purified, inac-
tivated by b-propiolacton and lyophilized. ‘‘Vaccin rabique Pas-
teur” was reconstituted in the appropriate solvent before being
administrated.
2.8. Assessment of safety and tolerability
Pain intensity at needle insertion and during vaccine and saline
solution injections was based on volunteers’ self-evaluation using a
Visual Analog Scale [27] (scores ranged from 0 to 10). At each site,
when incomplete injection using IDJ occurred, all pain scores (i.e.
also from the IDS and IM injections) were discarded.
Adverse Events (AE) were categorized as Solicited AE (SolAE)
and Unsolicited AE. SolAE were predefined in the subject’s Case
Report Form (CRF). SolAE were recorded within the reactogenicity
period (30 min after the injection, the evening following the injec-
tion and daily thereafter for 3 days and until the AE was resolved).
Local SolAE are Pain, Redness and Pruritus at injection site. Pain
subsequent to injection was evaluated during reactogenicity per-
iod at each injection site using the following scores: 0 for ‘‘absence
of pain”, 1 for ‘‘painful on touch”, 2 for ‘‘spontaneously painful”.
Redness was assessed using the following score: 0 for ‘‘absence
of redness”, 1, 2 and 3 considering redness diameters P3 mm,
P20 mm and P50 mm, respectively. Pruritus was assessed using
the following score: 0 for ‘‘absence of pruritus”, 1 for ‘‘mild inten-
sity”, 2 for ‘‘moderate intensity”, and 3 for ‘‘severe intensity”.
Systemic SolAE were listed as follows: headache, malaise, fever
(P38 C), chills, asthenia, nausea, arthralgia, myalgia, dizziness
and gastrointestinal disorders. All AE were evaluated by the inves-
tigator and recorded in the subject’s CRF.
2.9. Assessment of immunogenicity
The immunogenicity was assessed by measuring the humoral
response. Rabies VNA titers were analyzed in serum samples
obtained at each visit by Rabies Neutralization Test using the Rapid
Fluorescent Focus Inhibition Test (RFFIT; [28,29]). An antibody titer
of 0.5 IU/mL was considered as the threshold for protective immu-
nization of the subjects [22].
2.10. Statistical analyses
All safety and immunogenicity data analyses were performed at
the VIC and at the Swiss Rabies Center of the Institute of Virology
and Immunology. GraphPad Prism 6, R-software (R DevelopmentIM (Group C) routes.
Group B Group C Overall
21 21 64
10 (47.6) 12 (57.1) 31 (48)
11 (52.4) 9 (42.9) 33 (52)
20.4/43.6 19.6/36.9 18.6/43.6
25.8 ± 6.3 23.9 ± 4.0 25.1 ± 5.6
19.03/28.41 18.14/30.72 18.14/31.64
22.6 ± 2.6 22.2 ± 3.1 22.6 ± 3.0
A). In the last column, it represents the number of subjects for the three groups.
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statistical analyses.
Pain intensities at needle insertion and at product injection site
were compared between injection devices using the Mann Whit-
ney test. Pain, redness and pruritus at injection site were compared
between groups following vaccination for each time point of the
reactogenicity period using a 2-way analysis of variance (ANOVA)
combined with Tukey’s multiple comparison tests. Comparison of
RFFIT results between injection devices at the last study visit was
performed using a Kruskal-Wallis test combined with a Dunn’s
multiple comparison test. Rabies VNA titers were compared
between study groups at each study visit using an ANOVA
(repeated measures) test combined with a Bonferroni Multiple
Comparison Test.
2.11. Data exclusion
Due to protocol deviation, 1 subject from group B and 1 from
group C were excluded from analyses reducing the number of sub-
jects from 66 to 64 and the total number of injections included in
the analyses from 198 to 192 for each injection route (IDJ, IDS, IM).
All IDS and IM injections were successfully performed. Regard-
ing IDJ, 165 injections were considered as complete while 27 injec-
tions were considered as incomplete. Until the 75th injection, the
rate of IDJ complete injections was low at 67% (50 complete injec-
tions out of 75). After an additional training of the operators, the
rate of IDJ complete injection reached 98% (115 complete injec-
tions out of 117). The two failures were due to an operator error
during the device preparation.b
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Fig. 2. (a): Pain score at needle insertion for the 3 routes (all sites pooled, number of
insertions: 165  IDJ, 165  IDS, 165  IM, ****: p < 0.0001). (b): pain score at
vaccine injection for the 3 routes (all sites pooled, number of injections: 57  IDJ,
52  IDS, 56  IM, **: p = 0.0028, ***: p = 0.0001). (c): pain score at saline solution
injection for the 3 routes (all sites pooled, number of injections: 108  IDJ,
113  IDS, 109  IM, ****: p < 0.0001). Pain score: volunteers’ self-evaluation based
on the Visual Analog Scale from 0 to 10. Mean value +/ SD per group. Mann-
Whitney test. ns = not significant.3. Results
Whatever the injection route, the results (safety, tolerability
and immunogenicity) did not show any significant variation
regarding the position of the injection site either on the forearm
or on the deltoid. Therefore for each route, the data were pooled
by area (forearm, deltoid).
3.1. Safety and tolerability evaluation
3.1.1. Pain intensity at needle insertion and at products injection
The results indicate a significant decrease of pain at needle
insertion using IDJ compared with IDS and IM (p < 0.0001) (Fig. 2a).
Vaccine injection with IDJ generated less pain compared to both
IDS (p = 0.0028) and IM (p = 0.0001) (Fig. 2b). No difference in pain
intensity was observed following saline solution injection between
IDJ and IDS. Pain at saline solution injection by both IDJ and IDS
routes were significantly higher when compared to IM
(p < 0.0001) (Fig. 2c).
3.1.2. Reactogenicity evaluation of local SolAE
There was no significant difference regarding the occurrence of
pain after vaccine injection between IDJ and IDS over the reacto-
genicity period. Compared to both IDJ and IDS, IM injection of vac-
cine induced more frequently pain the evening after injection
(p = 0.0001) (Fig. 3a). There was no significant difference regarding
the occurrence of pain after saline injection between IDJ and IDS
over the reactogenicity period; they both induced pain very rarely.
Compared to both IDJ and IDS, IM injection of saline solution
induced pain more frequently 30 min (p = 0.0007 and p = 0.0026)
and the evening (p < 0.0001 and p = 0.0001) after injection
(Fig. 3b).
There was no significant difference regarding the occurrence of
redness after vaccine injection between IDJ and IDS. They both fre-
quently induced redness during the reactogenicity period. IMinjection of vaccine induced no redness during the reactogenicity
period (Fig. 4a).
IDJ injection almost always induced redness 30 min after saline
solution injection; the difference with both IDS and IM was highly
significant (p < 0.0001). For the other time points, the 3 routes
were similar and induced redness after saline injection less fre-
quently compared to vaccine injection (Fig. 4b). It is noticeable that
the redness at 30 min with IDJ is more frequent after saline solu-
tion injection compared to vaccine injection.
There was no significant difference regarding the occurrence of
pruritus after vaccine injection between IDJ and IDS. The maximum
occurrences of pruritus occurred at Day 1 and Day 2. IM vaccine
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Fig. 3. (a) Pain following vaccine injection with IDJ, IDS and IM at different time
points (all sites pooled, number of injections: 57  IDJ, 52  IDS, 56  IM). (b) Pain
following saline solution injection with IDJ, IDS and IM at different time points (all
sites pooled, number of injections: 108  IDJ, 113  IDS, 109  IM).
Fig. 4. (a) Redness following vaccine injection with IDJ, IDS and IM at different time
points (all sites pooled, number of injections: 57  IDJ, 52  IDS, 56  IM). (b)
Redness following saline solution injection with IDJ, IDS and IM at different time
points (all sites pooled, number of injections: 108  IDJ, 113  IDS, 109  IM).
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Fig. 5. Pruritus following vaccine injection with IDJ, IDS and IM at different time
points (all sites pooled, number of injections: 57  IDJ, 52  IDS, 56  IM).
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(Fig. 5). Whatever the route, saline solution injection induced no
significant pruritus.
3.1.3. Reactogenicity evaluation of systemic SolAE
Forty-one systemic SolAE were recorded in the overall study.
Headache was the most common systemic SolAE recorded in the
study, followed by gastrointestinal disorders, asthenia, dizziness,
malaise, nausea, myalgia and fever.
18 systemic SolAE were related to the vaccine. No systemic
SolAE was assessed as related to the devices.
3.1.4. Reactogenicity evaluation of Unsolicited AE
Ninety-eight Unsolicited AE have been reported from 43 sub-
jects during the study. 21 participants did not present any Unso-
licited AE. 83 Unsolicited AE were not related to the study, 9
were related to the vaccine, 4 to IDS and 2 to IM. Hematomas were
reported as related to ID or IM classical syringes. No Unsolicited AE
was related to DebioJectTM. No Serious Adverse Event (SAE) was
reported during the study.
3.2. Immunogenicity evaluation
The second objective of this study was to evaluate immuno-
genicity of the IDJ route compared to IDS and IM routes. None of
the subjects had detectable rabies VNA before receiving the first
dose of vaccine. All study participants were above threshold of pro-
tection (0.5 IU/ml) at last study visit, 56 days after first vaccination
(Fig. 6a). Consequently, all participants were considered as prop-
erly immunized against rabies at the end of the study. In addition,
no significant differences between groups were observed in rabiesVNA titers at any study visit (Fig. 6b). In this study, the humoral
immune response following rabies vaccine administration with
IDJ (0.1 ml) was similar to IDS (0.1 ml) and IM (0.5 ml).
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Fig. 6. (a) Geometric Mean Titers (GMT) calculated after logarithmic transforma-
tion (log 5) of antibody titers, per group at screening, first vaccination (D0), second
vaccination (D7), third vaccination (D28), and 56 days after the first vaccination
(D56). Error bars represent 95% confidence intervals. Threshold of protection:
Log5(0.5)  0.43. (b) Comparative assessment of rabies titers in Group A, B or C at
day 56. Graph represents individual or mean value +/ SD of rabies virus
neutralizing titers (IU/ml) per group (21xIDJ, 22xIDS, 21xIM).
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An essential aspect for successful commercial use of intrader-
mal injection tools is the guarantee of complete, reproducible
and user-independent insertion of the microneedle within the tar-
geted tissue. Incomplete insertion may lead to leakage during
injection, limiting the accuracy of the dose to be delivered. The skin
behaves like a visco-elastic medium [30] which deforms when a
force is applied on its surface. Depending on the injection site, this
deformation may vary between a few tens of micrometers up to a
few millimeters. In any case, it will be at least similar to the length
of the micro-needle and may therefore prevent it from penetrating
the skin. This issue is obviously not present in IDS injections, where
the length of the needle is large compared to the skin deformation.
One way to facilitate tissue penetration is to limit the contact sur-
face of the microneedle with the tissue, increasing the locally
applied pressure proportionally [31]. This is the approach used in
the Becton Dickinson’s Soluvia system where the needle is located
in a cavity, limiting the contact surface to the needle only, the
depth of penetration being controlled by walls present around
the needle [32]. Another approach, based on the viscous nature
of skin, consists of supplying the microneedle with sufficient veloc-
ity that the skin doesn’t deform significantly when impacted [33],
allowing a full penetration.
After insertion of the needle into the skin, the liquid solution
can be delivered. Typical amounts of fluid that are delivered repre-
sent a volume that will induce local deformation of the skin creat-ing the well-known bleb [32]. In order to allow bleb formation, it is
necessary to limit the pressure applied on the tissue during injec-
tion. Too high pressure applied to the skin may increase its fluidic
resistance and limit its ability to absorb fluid [34,35]. On the other
hand, some pressure still needs to be applied during injection to
maintain the microneedle within the skin. The inserter used in this
study has been designed to reconcile these two behaviors. The con-
cern of applying too high pressure during the injection led the
experimenters in the first series of healthy volunteers to slightly
pull the inserter during injection leading to leaks or partial leaks
in about 30% of cases. After improvement of the material training
stressing the fact that the inserter had to be maintained firmly in
place, the success rate went up to 98% (the remaining 2% of failure
were due to an operator handling error during device preparation).
A crucial part of the present trial was the assessment of compar-
ative pain perceived by the volunteers using the three different
injection methods: IDJ, IDS and IM. Particular attention has also
been paid to distinguish between the pain felt at the insertion of
the needle into the skin, which seems mostly related to the design
of the device and its physical interaction with the tissue, from the
pain felt at injection, which may be strongly influenced by the
chemical formulation of the injected substance.
The pain felt at the insertion site of the needle was significantly
lower for IDJ than for both IDS and IM routes. This is compatible
with the lower invasiveness of the former method where a very
short needle is introduced within a few milliseconds. By using
IDS, the healthcare provider may puncture back and forth repeat-
edly to find the right spot for injection whereas the needle has to
cross several layers of tissue using IM injection. Pain induced by sal-
ine solution injection was comparable in IDJ and IDS, both inducing
more pain than IM injection. This might be explained by the
mechanical constraints in the tissues due to the volume of liquid
delivered, being higher in the skin compared to muscle, which
induces more tissue damage [3]. It is noticeable that although the
pain at IM injection was similar in vaccine and saline solution, the
pain at vaccine injection was significantly lower compared to saline
injection in both IDS and IDJ. This might be explained by a specific
effect of the vaccine at IDJ and IDS injection sites which was absent
in IM injection. With both IDJ and IDS, pain after injection was only
due to the vaccine product itself, whereas pain was negligible with
saline solution indeed. In some cases, IM injection of saline solution
induced pain during the reactogenicity period. This may have been
due to mechanical constraints induced in muscles.
IDJ injection of saline solution almost always produced redness
30 min after injection. This might be explained by the reduced
depth of injection or by the mechanical impact of the microneedle
to the skin due to its penetration speed. This effect seemed to be
reduced by the vaccine. In contrast, for the following time points
with IDJ and IDS, redness frequency and severity were usually
higher with vaccine compared to saline. For both IDJ and IDS, the
vaccine itself had an effect on redness. For vaccine and saline solu-
tion, IM injection almost never induced redness or pruritus, which
might be explained by the depth of the injection.
With IDJ and IDS, pruritus after injection was only due to the
vaccine product itself.5. Conclusion
In accordance with the very small size of its needle, DebioJectTM
induced significantly less pain at needle insertion than IDS and IM.
It is also noticeable that injection using DebioJectTM was signifi-
cantly less painful compared to IDS and IM injections during rabies
vaccination.
A reduced dose of rabies vaccine (in this case, 0.1 ml instead of
0.5 ml) administered with IDJ induced a humoral immune
1788 P. Vescovo et al. / Vaccine 35 (2017) 1782–1788response similar to a reduced dose delivered by IDS or to a full dose
delivered by IM. This result is in accordance with previously pub-
lished clinical data [1].
This study clearly shows that the DebioJectTM device is safe, well
tolerated and able to deliver at least 100 ll of vaccine into the der-
mis with high reliability and accuracy. Further studies need to be
conducted in order to confirm these features in different popula-
tions, e.g. elderly or pediatric. In addition, improved immune
responses may be expected due to the very precise control of the
depth of injection allowing administration of the vaccine in the
best-suited areas regarding the abundance of the targeted immune
effectors.
Considering the drawbacks of the Mantoux method when per-
formed by healthcare workers without high level of expertise as
in this study, DebioJectTM offers the potential for fully studying
and developing this route of injection and its benefits like dose
sparing.
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